Siemens Healthineers and biotechnology firm Biogen are collaborating to develop MRI software applications for quantifying key markers of multiple sclerosis (MS) disease activity and progression.
The agreement brings together Siemens' experience in medical imaging with Biogen's background in neurology, according to the vendors. Siemens and Biogen said they are working to develop and validate automated applications to quantify key markers of MS -- including new T2 lesions and atrophy -- to help facilitate more-informed treatment decisions.
